COPD

A new study shows the underutilized test could reveal an additional 9% of asthma diagnoses and potentially 8% of asthma-COPD overlap syndrome cases.

How the aclidinium bromide trial brings novel perspective to COPD care.

The chronic respiratory disease is often under-diagnosed in female patients.

New ASCENT-COPD data show the therapy's benefit in reducing cardiovascular events among high-risk patients, along with significant exacerbation reduction.

The fixed-dose therapy was shown to reduce exacerbations, regardless of patient history, among those with increased cardiovascular risk.

What the introduction of aclidinium/formoterol could mean for patients with COPD.

The approved label update now indicates the therapy delays disease progression when used in combination with an approved oral background PAH therapy.

The most recent CDC data, presented at CHEST 2019, show nearly 1500 patients have reported an associated lung injury, and 33 have died.

A new study shows adult e-cigarette use in the US was steadily dropping since 2014— before spiking in 2018 among adults aged 18-24 years.

Trelegy Ellipta could become the first triple-combination, single-inhaler therapy approved for the treatment of both asthma and COPD.

An expert with the American Lung Association will lead discussion on one of the greatest drivers of death in the US.

The investigative ICS/LAMA/LABA inhaler therapy reported positive findings from its phase 3 ETHOS trial in August, though the results were not included in the FDA application.

The 12-year update highlights promising novel therapy classes, and sets disparities between pediatric and adult chronic cough treatment.

Results from the TRIMARAN and TRIGGER trials show significant benefits for 2 different doses of the ICS/LABA/LAMA combination.

A new study from ERS showed the technological material common among training athletes could help physicians monitor patients with COPD.

A new study from the ERS International Congress shows a trio of air pollutants are associated with significant increases in all-cause infant mortality in the UK.

A new study shows that approximately one-quarter of adults aged 18-34 years old with a medical condition have used marijuna in the past month.

A six-month regimen of the oral therapy showed patients with out-of-proportion PH improved their six-minute walking test scores.

Obstructive sleep apnea has been consistently underdiagnosed in US populations. Are screening methods enough?

Addressing the drivers of poor sleep conditions is among the many ways a physician can treat patients without prescription.

How a pattern of poor sleep could begin a cycle of worsened respiratory and cardiovascular health.

Dr. Rizzo provides a look into the current methods of COPD screening, and how patient treatment potential is changed.

How do at-risk exacerbation patients present, and what developing therapies could benefit them?

Investigative triple therapy PT010 from AstraZeneca has reached primary outcome results versus a pair of standard dual inhaled therapies.

What is the large-scale study looking to bring to clinical respiratory health understanding?

In what ways do the respiratory conditions differentiate in progression and care options?

A 600-city analysis of particulate matter found daily exposure is linked to worsened mortality rates, particularly in areas with higher mean temperatures.

A new study found significantly greater COPD development risk among middle-aged women who eat processed meat—and doubly worse risk for those who also smoke and have unhealthy diets.

Analysis from the CARDIA Lung study found patients with worsened FEV1 are at greater risk for emphysema, regardless of their smoker status.

Study of more than 650 COPD patients found that CRP-guided prescribing resulted in a lower percentage of patients who reported antibiotic use.